On 5th April 2024, over 60 researchers braved the train strikes and gusty weather to gather at Lady Margaret Hall in Oxford and engage in a day full of scientific talks, posters and discussions on the topic of adaptive immune receptor (AIR) analysis!
When designing machine learning algorithms with the aim of accelerating the discovery of novel and more effective therapeutics, we often care deeply about their ability to generalise to new regions of chemical space and accurately predict the properties of molecules that are structurally or functionally dissimilar to the ones we have already explored. To evaluate the performance of algorithms in such an out-of-distribution setting, it is essential that we are able to quantify the data shift that is induced by the train-test splits that we rely on to decide which model to deploy in production.
For our recent ICML 2023 paper Drug Discovery under Covariate Shift with Domain-Informed Prior Distributions over Functions, we chose to quantify the distributional similarity between two sets of molecules through the Maximum Mean Discrepancy (MMD).
Continue readingWe’ve been investigating deep learning-based protein-ligand docking methods which often claim to be able to generate ligand binding modes within 2Å RMSD of the experimental one. We found, however, this simple criterion can conceal a multitude of chemical and structural sins…
DeepDock attempted to generate the ligand binding mode from PDB ID 1t9b
(light blue carbons, left), but gave pretzeled rings instead (white carbons, right).
OPIG’s growing immunoinformatics team continues to develop and openly distribute a wide variety of databases and software packages for antibody/nanobody/T-cell receptor analysis. Below is a summary of all the latest updates (follows on from v1.0 and v2.0).
Continue readingOver the next few days, researchers from around the world will be gathering in Sheffield for the 9th Joint Sheffield Conference on Cheminformatics. As one of the organizers (wearing my Molecular Graphics and Modeling Society ‘hat’), I can say we have an exciting array of speakers and sessions:
It has traditionally taken place every three years, but despite the global pandemic it is returning this year, once again in person in the excellent conference facilities at The Edge. You can download the full programme in iCal format, and here is the conference calendar:
Continue readingLast month, I had the privilege to attend the Keystone Symposium on Computational Design and Modeling of Biomolecules in beautiful Banff, Canada. This conference gave an incredible insight into the current state of the protein design field, as we are on the precipice of advances catalyzed by deep learning.
Here are my key takeaways from the conference:
Continue readingBeing a jack of all trades brings to mind someone who has extensive multidisciplinary expertise and is equipped with many tools in their toolbox to solve different problems. A jack of all trades is a great succinct description for computational chemists in drug discovery.
Recently I had a great conversation with Dr. Arjun Narayanan, a Senior Research Scientist at Vertex Pharmaceuticals and a jack of all trades as a computational chemist. In this blog post, I’ll describe what he does as a computational chemist, the problems he solves, and the new tools he’s looking forward to adding to his toolbox.
From 19th-22nd February I was fortunate enough to participate in the joint Keystone Symposium on Next-Generation Antibody Therapeutics and Multispecific Immune Cell Engagers, held in Banff, Canada. Now in their 51st year, the Keystone Symposia are a comprehensive programme of scientific conferences spanning the full range of topics relating to human health, from studies on fundamental bodily processes through to drug discovery.
Continue readingOPIG recently celebrated its 20th year; and on 10 January 2023 I gave a talk just a day before the 10th anniversary of BLOPIG’s first blog post. It’s worth reflecting on what’s stayed the same and what’s changed since then.
Continue readingWhen I started my PhD in late 2018, AI hadn’t really entered the field of de novo protein design yet – at least not in a big way. Rosetta’s approach of continually ranking new side chain rotamers on a fixed backbone was still the gold standard for the ‘structure-to-sequence’ problem. And of course before long we had AI making waves in the structure prediction field, eventually culminating in the AlphaFold2 we all know and love.
Now, towards the end of my PhD, we are seeing the emergence of new generative models that learn from existing pdb structures to produce sequences that will (or at least should) fold into viable, sensible and crucially natural-looking shapes. ProtGPT2 is a good example (https://www.nature.com/articles/s41467-022-32007-7), but there are several more. How long before these models start reliably generating not only shapes but functions too? Jury’s out, but it’s looking more and more feasible. Safe to say the field as a whole has evolved massively during my time as a graduate student.
Continue reading